Esperion

Discussion in 'Esperion' started by anonymous, Nov 5, 2019 at 4:11 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Yep another bad quarterly report. The hits just keep coming with Esperion. Missed their estimates again. More losses as they just keep adding up. Lawsuit not going well despite the legal firm they hired. Nothing has gone right since the start.
     

  2. anonymous

    anonymous Guest

    We’re pretty excited to be joining on with the well vetted team at ESPR. Obviously with COVID it’s been a -frenetic launch environment but now it’s time to shine. The docs seem Uber excited about the drug and outcomes, fresh blood should help.elevate this to its rightful potential and place in the cardiovascular armamentarium… first second is a powerful space to be in given the large unmet need! Let’s go!
     
  3. anonymous

    anonymous Guest

    Still blaming covid 3 years later!!The sales people are all underperformers with sketchy backgrounds. Another nice try asshole!
     
  4. anonymous

    anonymous Guest

    Absolutely stunning that investment firms still hold shares of this dog. There sure are some dumbfucks on Wall St.
     
  5. anonymous

    anonymous Guest

    COVID excuse again ! - Pathetic

    Docs seem " Uber " excited ? - You sir, will soon be employed as a Uber driver. Sorry that you went through the Scientific Hiring Process.

    Fresh blood should help elevate ? - Wasn't the Scientific Hiring Process a success ? Are you donating at the Red Cross ?

    Sunshine...you are living in a Fantasy world.
     
  6. anonymous

    anonymous Guest

    As a relative newcomer, I’ve got to say that I’m pretty excited about the opportunity here. Some people have a hard time understanding the place and the role and positioning of the product, let’s be honest it’s not a Crestor. This can still be a blockbuster product without being first line. There are so many patients who are not at LDL goal in and who either cannot, or will not take a statin. Needles are not a great alternative. Insurance is also a big hurdle for these, so I’m figuring we can probably be at $1 billion a year in sales by 2025.
     
  7. anonymous

    anonymous Guest

    The culture was set during the scam interview process.
    -Karen
     
  8. anonymous

    anonymous Guest

    Take another hit on the bong dipshit. This is a fantasy land post. Billions???? This had been a huge failure to date. Keep dreaming loser.
     
  9. anonymous

    anonymous Guest

    No need to be rude, Karen Balboa.
     
  10. anonymous

    anonymous Guest

    I advise you to do your research on statins. They are not needed. Search for the real information, not the Pharma generated promotional study data.

    Start with the Number Needed to Treat, Absolute Risk Reduction. Look at adverse events and diabetes, Alzheimer's.

    This will be a good start.
     
  11. anonymous

    anonymous Guest

    Exactly… bempo isn’t a statin! It’s a setup that almost can’t be dreamed or imagined. To the moon!
    Negative Nellie is left in the dust, outside trying to look in. Sad.
     
  12. anonymous

    anonymous Guest

    Dumpo bempo.

    Not needed.

    What is the Number Needed to Treat and Time to treat, to prevent 1 event?

    Bet I don't get an answer here. No Clinical discussion from the Scientifically Hired Elites.
     
  13. anonymous

    anonymous Guest

    Answer finance and BD questions that you avoided first, bitch.
     
  14. anonymous

    anonymous Guest

    The stock price says it all. Bempo not needed.
     
  15. anonymous

    anonymous Guest

    No Finance and BD discussion from the cackling bitch Karen
     
  16. anonymous

    anonymous Guest


    Oh shut up! your a little pip squeak, goof who is a nothing surfing our site.. Why?

    You’re nothing but a COTTON-HEADED NINNY MUGGIN! Bahahah
     
  17. anonymous

    anonymous Guest

    More insults from the Ann Arbor crowd. We confronted for a clinical discussion the insults start. This drug is nothing more than a fart in a windstorm. Look at the stock depletion of 97% in last 4 years. That's a massacre!!
     
  18. anonymous

    anonymous Guest

    OK, so sales have fallen a little short of expectations up to this point. The fact of the matter is that we now have outcomes data and a tremendous amount of acceleration behind our sales momentum . NASCAR doesn’t lie, we know our assets can swing in the marketplace. EZ pickings lie ahead.
     
  19. anonymous

    anonymous Guest

    Yep nothing like a dipshit NASCAR fan. Likely never graduated high school and dipping chewing tobacco. In fact it probably helps lower LDL!! Stop the stupid posts about how great Esperion is. It's a third rate company with a second rate drug. The market responded accordingly to your precious Outcomes Data. Why else would DS withhold payment and in typical Esperion fashion they sue over their crappy data. What a tent in the woods outfit!!
     
  20. anonymous

    anonymous Guest

    Bitch Karen still cackling